FDA Inspection 1269495 — Evonik Rexim (Nanning) Pharmaceutical Co. Ltd.
The FDA completed an inspection of Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. on Apr 11, 2025 in Nanning. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 11, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nanning (China)